Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.
about
Parkinson's disease as a result of agingImproving the physiological realism of experimental models.Nesfatin-1 protects dopaminergic neurons against MPP+/MPTP-induced neurotoxicity through the C-Raf-ERK1/2-dependent anti-apoptotic pathwayMotor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease.Toxin-induced models of Parkinson's disease.Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian ratsPriming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian ratsLoss of Striatonigral GABAergic Presynaptic Inhibition Enables Motor Sensitization in Parkinsonian Mice.Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity.MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease.Noradrenaline and Parkinson's disease.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Aspects of innate immunity and Parkinson's disease.Concentrations of vitamins A, C and E in elderly patients with Parkinson's disease.Neuroprotective effects of a variety of pomegranate juice extracts against MPTP-induced cytotoxicity and oxidative stress in human primary neurons.Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.Targeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors.Is "Parkinson's disease" one disease?Parkinson's disease in 1984: an update.Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.Genetic elimination of dopamine vesicular stocks in the nigrostriatal pathway replicates Parkinson's disease motor symptoms without neuronal degeneration in adult mice.Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study.MPTP parkinsonism.Superoxide is the critical driver of DOPAL autoxidation, lysyl adduct formation, and crosslinking of α-synuclein.Cellular and Molecular Aspects of the β-N-Methylamino-l-alanine (BMAA) Mode of Action within the Neurodegenerative Pathway: Facts and Controversy.Synaptic plasticity may underlie l-DOPA induced dyskinesia.Prevention of progression in Parkinson's disease
P2860
Q28084395-2996659B-FD48-4061-A874-577363375B8CQ30714211-BE477008-1CA4-4C51-8816-06A28873A435Q30835631-F480F5A4-EBAD-40B2-A207-46C7E601A7C4Q33735320-02C0FD9C-E02E-49A4-9651-B205BE0B289CQ33834247-8AB9D29C-E30A-4D37-9608-E557A1FEBA8DQ33843073-4813F97E-020B-4E28-A27F-E7A23C5E368FQ33844749-D8F07937-5BA6-47DD-BE2E-38D353A8C6C9Q33917299-864B101A-0F55-446A-BEF2-71E4D5837536Q34044620-05261F1B-453E-4032-B8EF-E13E07931266Q34131256-A409B26C-EE65-4D4D-ADC2-2242570DEB24Q34492283-4C5268EC-65C8-4B63-92C4-D29919969316Q34625772-B6E8F0DD-6563-4C9C-BB2A-D7F78C359949Q34660052-44C87F24-E2D6-43BA-ADD3-455FDB120FAAQ35013240-135B6C48-97F1-410F-875E-8FF1107F93D5Q35589979-6F3E2D5D-149D-4532-A925-16F4496554C3Q35813131-0EB93FD2-F083-4DFF-BE1A-AE0712C989DBQ36683141-A7F49EB5-4988-44E2-A8DF-7FF141B3E78AQ37275312-C674F30C-86E2-4F94-8F7D-97F795A4FFE8Q37683630-F24839EB-8047-4691-AAF2-7AD7A128B82FQ38009736-9158C8E3-2614-45D5-80A2-DD1CE2891C19Q38668881-6CB4EDC7-CBD4-49D0-8B6B-D3E171401A7FQ40191579-D195FD2E-BB15-4B83-973B-4D189DE5B71DQ41591036-9F5F4F88-4E5A-497F-AD84-7B376E40383AQ41927560-21965B3F-F551-48AA-A319-6E4E73A40E94Q42205495-3B9199F8-BD51-4FDD-A124-F40B11C0F7BCQ43014664-28C420F9-25F2-406E-9749-22A315B6B7E3Q46382550-706C170F-4E79-4F20-BF06-AFA8AD44DEB0Q47260999-5293AD15-D3FC-4C74-BCCF-45B14012772BQ50069510-1E96EDD4-26B8-4A32-A517-64195023DD24Q58486541-D5430407-AC05-473F-B8C5-F98E6EE0FB44
P2860
Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
1984年论文
@zh
1984年论文
@zh-cn
name
Parkinsonism induced by 1-meth ...... enesis of Parkinson's disease.
@en
Parkinsonism induced by 1-meth ...... enesis of Parkinson's disease.
@nl
type
label
Parkinsonism induced by 1-meth ...... enesis of Parkinson's disease.
@en
Parkinsonism induced by 1-meth ...... enesis of Parkinson's disease.
@nl
prefLabel
Parkinsonism induced by 1-meth ...... enesis of Parkinson's disease.
@en
Parkinsonism induced by 1-meth ...... enesis of Parkinson's disease.
@nl
P1476
Parkinsonism induced by 1-meth ...... enesis of Parkinson's disease.
@en
P2093
Langston JW
P304
P433
P577
1984-02-01T00:00:00Z